Menu
Recruiting NCT06515093

Study Assessing Complete Wound Healing by Comparing Surgenex® PelloGraft in Treating DFU and SanoGraft® in Treating VLU to SOC

No phase Interventional Diabetic Foot Ulcer Venous Leg Ulcer

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: PelloGraft, SanoGraft.
Who it may be relevant to
Registry conditions: Diabetic Foot Ulcer, Venous Leg Ulcer. Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
United States
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

A Randomized Post-Market Study Assessing Complete Wound Healing by Comparing Surgenex® PelloGraft in Treating Diabetic Foot Ulcers (DFU) and SanoGraft® in Treating Venous Leg Ulcers (VLU) to SOC Treatment

Overview

The purpose of this study is to compare Pellograft to standard of care modalities in treating diabetic foot ulcers in human subjects, and to compare Sanograft to standard of care in treating venous leg ulcers. The study will demonstrate wound healing outcomes with comparators including time to wound epithelialization, decrease in wound size, and total number of study product applications towards healing outcome. This information is important to the Centers for Medicare and Medicaid Services (CMS) and other payors in determining coverage policy and reimbursement for this product category.

Interventions

  • Other PelloGraft
    dual layer amnion/chorion-derived allograft
  • Other SanoGraft
    single layer amnion-derived allograft

Primary outcome measures

  • 100% epithelialization [Time frame: 12 weeks (DFU) or 16 weeks (VLU)]
Secondary outcome measures (1)
  • Time to Healing [Time frame: 12 weeks (DFU) or 16 weeks (VLU)]

Eligibility criteria

Inclusion criteria

  • Subject is at least 18 years of age
  • Diabetic Foot Ulcer Only - Subject has diagnosed Type 1 or Type 2 diabetes
  • Subject's wound is located on foot or ankle (DFU) or leg (VLU)
  • Subject has diabetic foot ulcer > 1.0 cm2 and ≤ 25 cm2 OR venous leg ulcer > 1.0 cm2 and ≤ 50 cm2
  • Subject has adequate circulation to affected extremity with TcPO2 results of ≥ 40 mm Hg on the dorsum of the affected foot or ABI results ≥ 0.7 and≤ 1.2 or Great Toe Pressure ≥ 50 mmHg
  • Subject is willing and able to comply with all protocol requirements
  • Subject is willing and able to provide informed consent or obtain consent from legal authorized representative (LAR)

Exclusion criteria

  • Subject is pregnant
  • Subject with diagnosed diabetes has HbA1C > 12 within 3 months Prior to randomization
  • Subject has > 30% reduction in wound size after 2-week run-in period
  • Subject has active infection, undrained abscess, or critical colonization of the wound with bacteria
  • Subject has osteomyelitis or joint capsule on investigator's exam or radiographic evidence or bone culture, histology, x-ray changes or MRI
  • Subject is on parenteral corticosteroids or any cytotoxic agents for 7 consecutive days during 30 days before screening. Chronic oral steroid use is not excluded if dose < 10 mg per day of prednisone
  • Subject is currently undergoing cancer treatment
  • Subject has used biologic skin substitutes within 14 days of enrollment
  • Subject has an allergy to suture material
  • Subject has life expectancy less than six-months as assessed by the investigator
  • Subject is participating in another clinical research study prior to this study completion

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Open label
Primary purpose
Treatment

Study locations

United States · 2 centers
  • ILD Research — Vista
  • Tulsa Wound Center — Tulsa

Identifiers

NCT: NCT06515093 · 24-SUR-001

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗